Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now

Carlo Patrono; C. Baigent

doi:10.1002/cpt.696

Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now

Carlo Patrono, C. Baigent

University of Oxford

Risultato della ricerca: Contributo in rivista › Articolo in rivista

22 Citazioni (Scopus)

Abstract

The aim of the present review is to analyze how thinking about the cardiovascular safety of nonsteroidal antiinflammatory drugs has evolved during the past two decades, and discuss to what extent the additional information from the Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen study may alter our current mechanistic understanding and/or clinical practice.

Lingua originale	English
pagine (da-a)	238-245
Numero di pagine	8
Rivista	CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume	102
DOI	https://doi.org/10.1002/cpt.696
Stato di pubblicazione	Pubblicato - 2017
Pubblicato esternamente	Sì

Keywords

Animals
Anti-Inflammatory Agents, Non-Steroidal
Cardiovascular Diseases
Cyclooxygenase 2 Inhibitors
Gastrointestinal Diseases
Humans
Pharmacology
Pharmacology (medical)
Prospective Studies
Randomized Controlled Trials as Topic
Risk Factors

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1002/cpt.696

Altri file e collegamenti

Cita questo

@article{257ad308a6a84528b023c5c9fc0f0f1d,

title = "Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now",

abstract = "The aim of the present review is to analyze how thinking about the cardiovascular safety of nonsteroidal antiinflammatory drugs has evolved during the past two decades, and discuss to what extent the additional information from the Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen study may alter our current mechanistic understanding and/or clinical practice.",

keywords = "Animals, Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Cyclooxygenase 2 Inhibitors, Gastrointestinal Diseases, Humans, Pharmacology, Pharmacology (medical), Prospective Studies, Randomized Controlled Trials as Topic, Risk Factors, Animals, Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Cyclooxygenase 2 Inhibitors, Gastrointestinal Diseases, Humans, Pharmacology, Pharmacology (medical), Prospective Studies, Randomized Controlled Trials as Topic, Risk Factors",

author = "Carlo Patrono and C. Baigent",

year = "2017",

doi = "10.1002/cpt.696",

language = "English",

volume = "102",

pages = "238--245",

journal = "CLINICAL PHARMACOLOGY & THERAPEUTICS",

issn = "0009-9236",

publisher = "Mosby Year Book Incorporated:6277 Sea Harbor Drive:Orlando, FL 32887:(800)654-2452, (407)345-4000, EMAIL: [email protected], INTERNET: http://www.mosby.com, Fax: (407)363-9661, (314)432-1380",

}

TY - JOUR

T1 - Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now

AU - Patrono, Carlo

AU - Baigent, C.

PY - 2017

Y1 - 2017

N2 - The aim of the present review is to analyze how thinking about the cardiovascular safety of nonsteroidal antiinflammatory drugs has evolved during the past two decades, and discuss to what extent the additional information from the Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen study may alter our current mechanistic understanding and/or clinical practice.

AB - The aim of the present review is to analyze how thinking about the cardiovascular safety of nonsteroidal antiinflammatory drugs has evolved during the past two decades, and discuss to what extent the additional information from the Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen study may alter our current mechanistic understanding and/or clinical practice.

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Cardiovascular Diseases

KW - Cyclooxygenase 2 Inhibitors

KW - Gastrointestinal Diseases

KW - Humans

KW - Pharmacology

KW - Pharmacology (medical)

KW - Prospective Studies

KW - Randomized Controlled Trials as Topic

KW - Risk Factors

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Cardiovascular Diseases

KW - Cyclooxygenase 2 Inhibitors

KW - Gastrointestinal Diseases

KW - Humans

KW - Pharmacology

KW - Pharmacology (medical)

KW - Prospective Studies

KW - Randomized Controlled Trials as Topic

KW - Risk Factors

UR - http://hdl.handle.net/10807/129808

UR - http://www.nature.com/clpt/index.html

U2 - 10.1002/cpt.696

DO - 10.1002/cpt.696

M3 - Article

SN - 0009-9236

VL - 102

SP - 238

EP - 245

JO - CLINICAL PHARMACOLOGY & THERAPEUTICS

JF - CLINICAL PHARMACOLOGY & THERAPEUTICS

ER -

Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo